Shape Therapeutics Unveils Promising Gene Therapy for Parkinson’s Disease

At the recent European Society of Gene and Cell Therapy conference in Seville, US biotech company Shape Therapeutics revealed encouraging early data on a new gene therapy that could one day change how Parkinson’s Disease is treated. The therapy, known as SHP-201, aims to tackle Parkinson’s at its root cause by reducing levels of alpha-synuclein, a protein that builds up abnormally in the brains of people with the condition. These clumps of protein damage nerve cells and are widely believed to drive the disease. A smarter delivery system To get its treatment into the brain, Shape developed a new type of viral delivery system called SHP-DB1, built from a modified version of the AAV5 virus. The challenge with most gene therapies for the brain is that they struggle to cross the blood-brain barrier, the natural defence that keeps harmful substances out of the brain but also blocks many medicines. In laboratory studies with monkeys, the SHP-DB1 system was able to slip through this barrier after a simple injection into the bloodstream. It reached deep brain regions crucial for movement, including the substantia nigra—the part most affected in Parkinson’s—where it successfully reached around 96 percent of neurons. This is a major step forward because most existing viral carriers either don’t reach the brain effectively or trigger immune reactions that prevent them from working properly. SHP-DB1 was designed to avoid these issues, showing strong delivery power and a lower chance of being blocked by antibodies. Targeting the source of the problem Once inside the brain, SHP-201 uses Shape’s RNAfix® technology to switch off the gene that makes alpha-synuclein. Instead of editing DNA directly, which can be risky, this approach targets RNA—the molecule that carries genetic instructions. By interrupting this process, the therapy stops cells from producing the harmful protein in the first place. Tests on brain cells grown from human stem cells showed that SHP-201 cut alpha-synuclein levels by more than 80 percent, and similar results were seen in mice. When the therapy was tested in monkeys, it again reduced the target gene’s activity by over 70 percent in key areas of the brain, including the substantia nigra. The treatment also appeared to be well tolerated, showing no major side effects in the animals tested. Why this matters At present, there is no treatment that slows or stops Parkinson’s Disease. Available drugs only help manage symptoms such as tremor and stiffness. A gene therapy like SHP-201 could, in theory, go further by halting or reversing the disease process itself. Shape’s chief technology officer, Adrian Briggs, called the findings a “key breakthrough,” saying the company is building a “one-and-done” therapy that could permanently reset the disease mechanism without altering a person’s DNA. What comes next The data so far come from preclinical studies, meaning the therapy has not yet been tested in people. The next stages will focus on safety testing and scaling up production before any human trials can begin. Based in Seattle, Washington, Shape Therapeutics is also using artificial intelligence to refine its delivery systems and manufacturing methods. The company hopes its technologies will eventually open the door to new treatments for a range of neurological conditions, not just Parkinson’s. If successful, SHP-201 could become one of the first truly disease-modifying therapies for Parkinson’s—a long-awaited breakthrough for millions of people worldwide.